The Board of Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company) is pleased to announce it has sponsored an observation autism trial in Chile, demonstrating successful results for treating the core symptoms of autism with medicinal cannabis extracts that Zelda is planning on taking into clinical trials.
The results demonstrated that in a cohort of 21 patients (median age of 9 years 10 months), cannabis extracts were significantly more effective than conventional medicines used, including atypical antipsychotics, and these extracts were well tolerated by the patients overall.
Patients in the study were treated over at least a 12-week period and were examined by electroencephalogram (EEG), neuropsychological analysis as well as metabolism and genetic tests. The patients in the study had not responded well to conventional treatments. Patients treated with cannabis extracts demonstrated significant improvements in at least one core symptom including social interaction, language or repetitive behaviors in 71.4% of cases and 66.7% of treated patients showing significant general overall improvement.
The results are being presented at the prestigious 23rd World Congress of Neurology in Kyoto, Japan on 16 – 21 September 2017.
The trial was managed by leading clinician Dr Gisela Kuester who is a highly regarded neurologist specialising in the diagnosis and treatment of autism. She also holds the position of Clinical Research Director at Fundación Daya.